The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting cautious optimism within the biotechnology sector, Guggenheim has adjusted its outlook on Amgen. According to reports, the firm raised its price target for the stock from $340 to $343 while maintaining a neutral rating. This adjustment follows quarterly results that exceeded analyst estimates for both earnings and revenue, leading the company to increase its full-year 2026 financial guidance.
Amgen's robust performance comes amid intensifying competition in the healthcare sector, with peer Gilead Sciences recently reporting strong results driven by antiviral sales. Per market data, AMGN shares are currently trading above Guggenheim's new price target, supporting the decision to maintain a neutral stance despite the improved forward-looking growth projections.
Amgen (AMGN) stood at $363.39 at close July 10, 2026, having reached a day high of $364.9. Investors are now looking toward broader market catalysts, including the release of the FOMC Minutes on July 8, which could impact risk sentiment for high-growth sectors like biotechnology.